Abstract
In Type I diabetes the observation of a decreased release of interleukin-2 (IL-2) and soluble IL-2 receptors by means of stimulated lymphocytesin vitro indicates that a primary immunoregulatory defect may be involved. To confirm this hypothesis we investigated the T-cell activation trend, evaluating the surface expression of IL-2 receptor (CD25), transferrin (CD71), HLA class II (DR), and CD69 phenotypes afterin vitro stimulation with phytohemagglutinin (PHA; 1 and 10 µg/ml) and concanavalin A (12.5 µg/ml) in six newly diagnosed Type I diabetics and six islet cell- and insulin autoantibody-positive first-degree relatives. As controls were studied six long-standing Type I diabetics and six healthy subjects. T-cell cultures from the four groups were performed on the same day and examined at 0, 24, 48, 96, 120, and 144 hr. Cytometric analysis was performed, keeping PBMC gating constant on the basis of physical parameters (scatter and volume). Using both PHA concentrations, a lower level of CD25, CD71, CD69, and DR antigen expression was found in newly diagnosed patients at all observation times with respect to control cultures (P<0.001). Unexpectedly, pre-Type I diabetic subjects, after 1 µg/ml of PHA, showed a significantly reduced expression of CD69 (P<0.001) and CD71 (P<0.001). The levels remained low, also with high PHA, at the different observation periods, while CD25 expression was found to be reduced in prediabetics only after 1 µg/ml of PHA (P<0.001). The long-standing patients showed a T cell activation trend very close to the latter. Our data show that in Type I diabetes and in the early phases of the disease, the initial activation signal(s) appears to be affected, particularly with one or more subsequent events necessary to initiate the appearance of “activation antigens.” This study suggests that the natural history of immunoregulation in pre-Type I and Type I diabetes is characterized by a primary defect in this system, which also persists in patients with long-standing disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Eisenbarth GS: Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360–1368, 1986
Cohen IR: Insulin-dependent diabetes mellitus. Curr Op Immunol 1:727–732, 1989
Rossini AA, Handler ES, Greiner DL, Mordes JP: Personal view. Insulin dependent diabetes mellitus hypothesis of autoimmunity. Autoimmunity 8:221–235, 1991
Gepts W, LeCompte PM: The pancreatic islets in diabetes. Am J Med 70:105–115, 1981
Drell DW, Notkins AL: Multiple immunological abnormalities in patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:132–143, 1987
Jackson RA, Morris AA, Haynes BF, Eisenbarth GS: Increased circulating Ia antigen-bearing T cells in Type I diabetes mellitus. N Engl J Med 306:785–788, 1982
Hayward AR, Herberger M: Culture and phenotype of activated T-cells from patients with Type 1 diabetes mellitus. Diabetologia 33:319–323, 1984
Buschard K, Damsbo P, Ropke C: Activated CD4+ and CD8+ T-lymphocytes in newly diagnosed Type 1 diabetes: A prospective study. Diabet Med 7:132–136, 1990
Al-Sakkaf L, Pozzilli P, Tarn AC, Schwarz G, Gale EAM, Bottazzo GF: Persistent reduction of CD4/CD8 lymphocyte ratio and cell activation before the onset of Type 1 (insulin-dependent) diabetes. Diabetologia 32:322–325, 1989
Zier KS, Leo MM, Spielman RS, Baker L: Decreased synthesis of Interleukin 2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 33:552–555, 1984
Kaye AK, Adri MNS, Soeldner JS, Rabinowe SL, Kaldany A, Kahn CR, Bistrian B, Srikanta S, Ganda OMP, Eisenbarth GS: Acquired defect in interleukin 2 production in patients with Type 1 diabetes mellitus. N Engl J Med 315:920–924, 1986
Giordano C, Pantó F, Caruso C, Modica MA, Zambito AM, Sapienza N, Amato MP, Galluzzo A: The interleukin 2 and soluble interleukin 2 receptor secretion defect “in vitro” in newly diagnosed Type I diabetic patients. Diabetes 38:310–315, 1989
Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science 243:355–361, 1989
June CH: Signal transduction in T cells. Curr Op Immunol 3:287–293, 1991
Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349–1356, 1990
Poulton TA, Gallagher A, Potts RC, Swanson Beck J: Changes in activation markers and cell membranes receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology 64:419–425, 1988
Creemers PC: Determination of co-expression of activation antigens on proliferating CD4+, CD4+CD8+ and CD8+ lymphocyte subsets by dual parameter flow cytometry. J Immunol Meth 97:165–171, 1987
Bach FH, Geller RL, Nelson PJ, Panzer S, Gromo G, Benfield MR, Inverardi L, Podack ER, Witson JC, Houchins JP, Alter BJ: A “minimal signal-stepwise activation” analysis of functional maturation of T lymphocytes. Immunol Rev 111:35–57, 1989
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057, 1979
Ad Hoc Expert Committee: Position statement. Prevention of Type I diabetes mellitus: Diabetes Care 13:1026–1027, 1990
Harter HL: Tests based on range and studentized range of samples from a normal population.In Order Statistics and Their Use in Testing and Estimation. Washington, DC, U.S. Government Printing Office, 1970
Alviggi L, Hoskins PJ, Johnston C, Tee DE, Pyke DA, Leslie RD, Vergani D: Pathogenesis of insulin-dependent diabetes: A role for activated T lymphocytes. Lancet 2:1363–1365, 1981
Giordano C, Pantó F, Caruso C, Modica MA, Amato MP, Galluzzo A: Markers of stimulated T lymphocyte activation at the onset of Type 1 (insulin-dependent) diabetes. Med Sci Res 16:423–424, 1988
Giordano C, Galluzzo A, Marco A, Pantó F, Amato MP, Caruso C, Bompiani GD: Increased soluble interleukin 2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res 8:135–138, 1988
Giordano C, Galluzzo A, Pantó F, Amato MP, Bompiani GD: In vitro lymphokine secretion by peripheral blood mononuclear cells after phytohaemoagglutinin stimulation in Type 1 diabetes. Diab Nutr Metab 3:277–284, 1990
Testi R, Phillips JH, Lanier LL: T cell activation via Leu-23 (CD69). J Immunol 143:1123–1128, 1989
Carrel S, Salvi S, Isler P, Rapin C, Hayoz D, Gallay P, Giuffré L: gp-33-38, an early human T cell activation antigen. J Immunol 144;2053–2062, 1990
Pelosi E, Testa U, Louache F, Thomopoulos P, Salvo G, Samoggia P, Peschle C: Expression of transferrin receptors in phytohemagglutinin-stimulated human T-lymphocytes. Evidence for a three-step model. J Biochem Chem 261:3036–3042, 1986
Neckers LM, Cossman J: Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2. Proc Natl Acad Sci USA 80:3494–3498, 1983
Zipris D, Lazarus AH, Crow AR, Hadzija M, Delovitch TL: Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune non obese diabetic mice. Evidence for thymic T cell anergy that correlates with the onset of insulitis. J Immunol 146:3763–3771, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giordano, C., de Maria, R., Todaro, M. et al. Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defectin vitro . J Clin Immunol 13, 68–78 (1993). https://doi.org/10.1007/BF00920637
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00920637